A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc
Cook Group Incorporated
Hutchmed
Ariceum Therapeutics GmbH
PharmaMar
Nuvation Bio Inc.
Hoffmann-La Roche
EpicentRx, Inc.
Clarity Pharmaceuticals Ltd
Advanced Accelerator Applications
Ipsen
RECORDATI GROUP
TerSera Therapeutics LLC
Novartis
Hutchmed
Hutchmed
Radiomedix, Inc.
Ipsen
Ipsen
Xencor, Inc.
Advanced Accelerator Applications
Novartis
Novartis
Novartis
Ipsen
Ipsen
Ipsen
Vanquish Oncology, Inc.
Ipsen
Clarity Pharmaceuticals Ltd
Ipsen
PharmaMar
Eli Lilly and Company
Pfizer
Novartis
Ipsen
Ipsen
Ipsen
Novartis
Hutchmed
Esanex Inc.
Mateon Therapeutics
Camurus AB
Mateon Therapeutics
Novartis
Molecular Insight Pharmaceuticals, Inc.
Merck Sharp & Dohme LLC
Pfizer
Novartis
Molecular Insight Pharmaceuticals, Inc.